Browse Category

NASDAQ:NVAX 6 November 2025 - 8 May 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.

Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax surged roughly 13% by Friday afternoon, building on gains after its quarterly results. The vaccine manufacturer topped first-quarter revenue expectations, driven more by licensing and supply agreements than any recovery in COVID-19 vaccine demand. Shares were changing hands at $10.45, with intraday volume topping 8.4 million, market data showed.

8 May 2026

NASDAQ:NVAX·NYSE:PFE·Pharmaceuticals·Stock Market

Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat

Novavax Inc. shares climbed as the vaccine maker’s first-quarter revenue topped Wall Street forecasts, lifted not by COVID-19 shot demand but by licensing and supply payments linked to its vaccine technology. Revenue came in at $139.5 million, Reuters said, beating analysts’ $78.3 million estimate from LSEG data.

7 May 2026

Earnings·NASDAQ:NVAX·Pharmaceuticals

Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax shares jumped Wednesday. The vaccine maker’s first-quarter revenue came in far ahead of Wall Street forecasts, buoyed by a $30 million payment from Pfizer and partner revenue, not from COVID-19 shot sales.

6 May 2026

Earnings Reports·NASDAQ:NVAX·Pharmaceuticals

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax shares ended Friday at $8.85, slipping roughly 6.4% during the session. U.S. markets remain closed over the weekend and will open again Monday.

31 January 2026

Earnings Reports·NASDAQ:NVAX·Pfizer·Pharmaceuticals·Stock Market

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer shares ended Thursday up 0.8%, closing at $26.10 after climbing Wednesday. The stock stayed comfortably within the mid-$20s, fluctuating between $25.75 and $26.31 during the session.

23 January 2026

NASDAQ:NVAX·NYSE:PFE·Pfizer·Stock Market

Pfizer stock ticks up as ViiV exit plan and Novavax vaccine deal keep PFE in focus

Pfizer shares climbed Thursday after the company announced two deals highlighting its strategy to transform its business. By afternoon, the stock had gained roughly 0.8%, reaching $26.10.

22 January 2026

LSE:GSK·NASDAQ:NVAX·NYSE:PFE·Pfizer·Pharmaceuticals·Stock Market

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer shares gained roughly 0.8%, hitting $25.73 by Wednesday afternoon. The Health Care Select Sector SPDR ETF climbed around 1.2%, while the S&P 500 tracker SPY edged up about 0.5%.

21 January 2026

NASDAQ:NVAX·NYSE:GSK·NYSE:PFE·Pharmaceuticals·Stock Market

Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

Novavax shares edged higher by about 1% in premarket Wednesday after announcing a licensing agreement with Pfizer for its Matrix‑M vaccine technology. The stock last changed hands at $8.28, marking a 0.98% increase.

21 January 2026

NASDAQ:NVAX·NYSE:PFE

Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

Pfizer shares slipped 0.7% to $25.47 Tuesday afternoon, after GSK and Shionogi announced Pfizer will exit HIV-focused ViiV Healthcare in a $1.9 billion deal. Pfizer is set to get $1.88 billion for its 11.7% stake, with the deal expected to close in Q1 pending regulatory approval. That day, the stock fluctuated between $25.11 and $25.65. ViiV chair David Redfern called the move a way to “simplify the shareholder structure.” Pfizer has also cautioned investors that 2026 could be challenging, as COVID-19 product sales decline, pricing pressures mount, and key patents expire.

20 January 2026

NASDAQ:NVAX·NYSE:PFE·Pharmaceuticals·Stock Market

Novavax stock today: NVAX closes up 6% as Singapore rolls out JN.1 Novavax COVID shot

Novavax Inc shares rose 6.1% on Friday to close at $7.13, outperforming in a mixed U.S. session as traders latched onto fresh signs of overseas demand for its updated COVID-19 shot. The stock traded about 38% below its 52-week high of $11.55 set on Jan. 7 last year, according to MarketWatch data. MarketWatch

3 January 2026

NASDAQ:NVAX·Pharmaceuticals·Stock Market

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

Novavax, Inc. closed on Friday, 5 December 2025 at $6.91 per share, giving the vaccine maker a market value of around $1.1 billion.Novavax Investor Relations+1

7 December 2025

NASDAQ:NVAX

Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Going into Monday, November 24, 2025, Novavax shares are coming off a choppy stretch.

24 November 2025

NASDAQ:NVAX·Stock Market

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax, Inc. reported Q3 2025 results and raised its full‑year adjusted revenue framework to $1.04–$1.06 billion. Management cited momentum from licensing, supply, and milestone revenue—while excluding Sanofi‑led sales and royalties from the outlook. The company also reaffirmed 2025 operating‑expense guidance. ir.novavax.com

6 November 2025

Biotechnology·Earnings Reports·EPA:SAN·NASDAQ:NVAX·Pharmaceuticals·Stock Market

NASDAQ:NVAX 6 November 2025 - 8 May 2026

Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat

Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer stock ticks up as ViiV exit plan and Novavax vaccine deal keep PFE in focus

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Novavax stock edges up premarket as Pfizer Matrix‑M pact puts $530 million-plus in play

Pfizer stock slips today as $1.9 billion ViiV exit and Novavax Matrix‑M deal land

Novavax stock today: NVAX closes up 6% as Singapore rolls out JN.1 Novavax COVID shot

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

TechStock² Updates

B2Gold (NYSEAMERICAN:BTG) surges 23% after Mali permit offsets Q2 earnings shortfall (B2Gold)

Intel (NASDAQ:INTC) Shares Jump 12.7% As New Head of Sales Tested on Performance

Palo Alto Networks (NASDAQ:PANW) shares steady after China review, valuation scrutiny highlights growth prospects

RTX Shares Approach 52-Week Peak as Missile Demand Sets Cash-Conversion Challenge

Palantir Shares (NASDAQ:PLTR) Gain Nearly $118 Billion Over a Week, Placing Higher Expectations on Performance

Top Stock Picks

AerCap

Constellation Energy

Cheniere Energy

Walt Disney

AIG

Live updates

Investment Disclaimer